JP2017530982A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530982A5 JP2017530982A5 JP2017518329A JP2017518329A JP2017530982A5 JP 2017530982 A5 JP2017530982 A5 JP 2017530982A5 JP 2017518329 A JP2017518329 A JP 2017518329A JP 2017518329 A JP2017518329 A JP 2017518329A JP 2017530982 A5 JP2017530982 A5 JP 2017530982A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- subject
- compound
- disorder
- sterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060932P | 2014-10-07 | 2014-10-07 | |
| US62/060,932 | 2014-10-07 | ||
| PCT/US2015/054551 WO2016057713A1 (en) | 2014-10-07 | 2015-10-07 | Neuroactive compounds and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020149725A Division JP2020196759A (ja) | 2014-10-07 | 2020-09-07 | 神経刺激性化合物およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017530982A JP2017530982A (ja) | 2017-10-19 |
| JP2017530982A5 true JP2017530982A5 (enExample) | 2018-11-15 |
Family
ID=55653736
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518329A Withdrawn JP2017530982A (ja) | 2014-10-07 | 2015-10-07 | 神経刺激性化合物およびその使用方法 |
| JP2020149725A Withdrawn JP2020196759A (ja) | 2014-10-07 | 2020-09-07 | 神経刺激性化合物およびその使用方法 |
| JP2022000454A Pending JP2022033285A (ja) | 2014-10-07 | 2022-01-05 | 神経刺激性化合物およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020149725A Withdrawn JP2020196759A (ja) | 2014-10-07 | 2020-09-07 | 神経刺激性化合物およびその使用方法 |
| JP2022000454A Pending JP2022033285A (ja) | 2014-10-07 | 2022-01-05 | 神経刺激性化合物およびその使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20170304321A1 (enExample) |
| EP (1) | EP3204011A4 (enExample) |
| JP (3) | JP2017530982A (enExample) |
| KR (1) | KR20170065637A (enExample) |
| CN (2) | CN112121171A (enExample) |
| AU (2) | AU2015330906A1 (enExample) |
| BR (1) | BR112017007053A2 (enExample) |
| CA (1) | CA2963938C (enExample) |
| IL (2) | IL292465B2 (enExample) |
| MX (2) | MX388694B (enExample) |
| MY (1) | MY202135A (enExample) |
| PE (1) | PE20170907A1 (enExample) |
| PH (1) | PH12017500639A1 (enExample) |
| RU (1) | RU2764702C2 (enExample) |
| SG (2) | SG10202011773UA (enExample) |
| WO (1) | WO2016057713A1 (enExample) |
| ZA (1) | ZA201702545B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI2753632T3 (fi) | 2011-09-08 | 2023-08-02 | Sage Therapeutics Inc | Neuroaktiivisia steroideja, koostumuksia ja niiden käyttöjä |
| RS67266B1 (sr) | 2013-03-13 | 2025-10-31 | Sage Therapeutics Inc | Neuroaktivni steroidi i postupci za njihovu upotrebu |
| KR102280614B1 (ko) | 2013-03-15 | 2021-07-21 | 글로벌 블러드 테라퓨틱스, 인크. | 헤모글로빈 조정을 위한 화합물 및 이의 용도 |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| AU2014369916A1 (en) | 2013-12-24 | 2016-06-16 | Durect Corporation | Uses of oxygenated cholesterol sulfates (OCS) |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| MX390271B (es) | 2015-07-06 | 2025-03-20 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos |
| FI3828194T3 (fi) | 2015-07-06 | 2025-07-17 | Sage Therapeutics Inc | Oxysteroleita ja menetelmiä niiden käyttämiseksi |
| MA42409A (fr) * | 2015-07-06 | 2018-05-16 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| US20190330259A1 (en) | 2016-04-01 | 2019-10-31 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| LT3481846T (lt) | 2016-07-07 | 2021-08-25 | Sage Therapeutics, Inc. | 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles |
| PT3494125T (pt) | 2016-08-02 | 2022-07-07 | Durect Corp | Composições compreendendo 5-colesten-3, 25-diol, 3-sulfato (25hc3s), ou seu sal farmaceuticamente aceitável, e, pelo menos, um oligossacárido cíclico |
| JP7149266B2 (ja) | 2016-09-30 | 2022-10-06 | セージ セラピューティクス， インコーポレイテッド | Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法 |
| MA46566A (fr) | 2016-10-18 | 2019-08-28 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| IL293231B2 (en) | 2016-10-18 | 2025-10-01 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| EP3335730A1 (en) * | 2016-12-15 | 2018-06-20 | Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) | Compounds for treating x-linked adrenoleukodystrophy |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US8604011B2 (en) * | 2004-09-27 | 2013-12-10 | The Regents Of The University Of California | Therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| GB0712494D0 (en) * | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| WO2009059961A2 (en) * | 2007-11-06 | 2009-05-14 | N.V. Organon | A method of hormone suppression in humans |
| BRPI0912362A2 (pt) * | 2008-05-09 | 2015-10-06 | Univ Emory | antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos |
| WO2010065709A2 (en) * | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| US20110319416A1 (en) * | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| WO2011028794A2 (en) * | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| FI2753632T3 (fi) | 2011-09-08 | 2023-08-02 | Sage Therapeutics Inc | Neuroaktiivisia steroideja, koostumuksia ja niiden käyttöjä |
| EP2841067A4 (en) * | 2012-04-25 | 2016-04-13 | Univ California | MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME |
| WO2014025942A1 (en) * | 2012-08-09 | 2014-02-13 | Emory University | Nmda receptor modulators and uses related thereto |
| CA2898863A1 (en) * | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| RU2021111681A (ru) * | 2013-03-13 | 2021-05-11 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, композиции и их применение |
| RS67266B1 (sr) | 2013-03-13 | 2025-10-31 | Sage Therapeutics Inc | Neuroaktivni steroidi i postupci za njihovu upotrebu |
| ES2970222T3 (es) * | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| WO2016007762A1 (en) * | 2014-07-09 | 2016-01-14 | Duke University | Compositions and methods for the repair of myelin |
| MA42409A (fr) * | 2015-07-06 | 2018-05-16 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
-
2015
- 2015-10-07 EP EP15849514.3A patent/EP3204011A4/en active Pending
- 2015-10-07 CN CN202011059273.5A patent/CN112121171A/zh active Pending
- 2015-10-07 MX MX2017004684A patent/MX388694B/es unknown
- 2015-10-07 RU RU2017115849A patent/RU2764702C2/ru active
- 2015-10-07 WO PCT/US2015/054551 patent/WO2016057713A1/en not_active Ceased
- 2015-10-07 US US15/517,886 patent/US20170304321A1/en not_active Abandoned
- 2015-10-07 PE PE2017000579A patent/PE20170907A1/es unknown
- 2015-10-07 IL IL292465A patent/IL292465B2/en unknown
- 2015-10-07 JP JP2017518329A patent/JP2017530982A/ja not_active Withdrawn
- 2015-10-07 MY MYPI2017000507A patent/MY202135A/en unknown
- 2015-10-07 SG SG10202011773UA patent/SG10202011773UA/en unknown
- 2015-10-07 CA CA2963938A patent/CA2963938C/en active Active
- 2015-10-07 AU AU2015330906A patent/AU2015330906A1/en not_active Abandoned
- 2015-10-07 SG SG11201702799UA patent/SG11201702799UA/en unknown
- 2015-10-07 CN CN201580063540.7A patent/CN107405352A/zh active Pending
- 2015-10-07 KR KR1020177012221A patent/KR20170065637A/ko not_active Ceased
- 2015-10-07 BR BR112017007053A patent/BR112017007053A2/pt not_active Application Discontinuation
-
2017
- 2017-04-02 IL IL251505A patent/IL251505B/en unknown
- 2017-04-06 PH PH12017500639A patent/PH12017500639A1/en unknown
- 2017-04-07 MX MX2021011939A patent/MX2021011939A/es unknown
- 2017-04-10 ZA ZA2017/02545A patent/ZA201702545B/en unknown
-
2020
- 2020-09-07 JP JP2020149725A patent/JP2020196759A/ja not_active Withdrawn
-
2021
- 2021-02-04 AU AU2021200721A patent/AU2021200721B2/en active Active
-
2022
- 2022-01-05 JP JP2022000454A patent/JP2022033285A/ja active Pending
- 2022-09-19 US US17/947,844 patent/US20230218638A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017115849A (ru) | Нейроактивные соединения и способы их применения | |
| US11160795B2 (en) | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus | |
| AU2012330885B2 (en) | Oral immediate release formulations for substituted quinazolinones | |
| CN104080339B (zh) | 高生物利用度的零价硫的制备和组合物及其用途 | |
| EP1715865B1 (en) | Hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid | |
| Singh et al. | Curcuma oil ameliorates hyperlipidaemia and associated deleterious effects in golden Syrian hamsters | |
| EP2521569B1 (en) | Combined treatment utilizing vb-201 | |
| JP5674676B2 (ja) | 結腸癌発生を予防または低減する方法 | |
| JP2016515575A (ja) | 細胞生存率を向上させるための組成物およびその使用方法 | |
| JPH10330251A (ja) | コレステロール低下剤 | |
| MXPA04012149A (es) | El uso de cianopirrolidinas sustituidas y prepraraciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas. | |
| JP5837919B2 (ja) | （ｅ）−４−カルボキシスチリル−４−クロロベンジルスルホンの改善された安定な水性製剤 | |
| EP2698159A1 (en) | Pitavastatin-containing preparation and method for producing same | |
| EP4461304A1 (en) | Composition for preventing or improving hepatic dysfunction | |
| EP4615462A1 (en) | Methods and compositions for treating wolfram syndrome | |
| EP2926817A1 (en) | Stable pharmaceutical composition for treating osteoporosis | |
| JP2008063322A (ja) | ＨＭＧ−ＣｏＡリダクターゼ阻害剤、トコフェロール類及びＣｏＱ１０を含有する医薬組成物 | |
| CN106937952A (zh) | 依折麦布和辛伐他汀的制剂 | |
| JP6227535B2 (ja) | 脂質異常症の予防又は治療薬 | |
| AU2017305661A1 (en) | New use of N,N-bis-2-mercaptoethyl isophthalamide | |
| CN110869019A (zh) | 用于治疗血脂异常的烟酰胺 | |
| WO2007116458A1 (ja) | 神経変性疾患治療薬 | |
| TW201538159A (zh) | 用於治療高膽固醇血症、高脂蛋白血疾病或動脈粥樣硬化之醫藥組合物及其製備方法 | |
| Marsili et al. | 31 Cerebellar Ataxia | |
| HK40004918B (en) | Compositions for improving cell viability and methods of use thereof |